Which Is a Better Investment, Boston Scientific Corporation or Penumbra, Inc. Stock?
Learn more about whether Boston Scientific Corporation or Penumbra, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Boston Scientific Corporation (NYSE:BSX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Boston Scientific (NYSE:BSX) Price Target Raised to $115.00
Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.
Boston Scientific: Q4 Earnings Snapshot
For the current quarter ending in March, Boston Scientific expects its per-share earnings to range from 66 cents to 68 cents. The company expects full-year earnings in the range of $2.80 to $2.87 per share.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank,
Wells Fargo Sticks to Their Buy Rating for Boston Scientific (BSX)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Boston Scientific (BSX – Research Report) yesterday and set a price target of
Boston Scientific Corporation: Boston Scientific announces results for fourth quarter and full year 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Boston Scientific (BSX) Surpasses Q4 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.
BioWorld1d
Boston Sci’s Farapulse tops $1B in 2024, bright prospects for 2025
As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...
MassDevice1d
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
medtechdive1d
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Boston Scientific remains bullish despite tariffs with sales buoyed by Minnesota tech
Boston Scientific, with approximately 10,000 employees in Minnesota, reported a fourth-quarter adjusted net profit of $1 ...
Boston Scientific sees FY25 adjusted EPS $2.80-$2.87, consensus $2.81
The company said, “The company estimates net sales growth for the full year 2025, versus the prior year period, to be in a range of approximately 12.5 to 14.5 percent on a reported basis, and ...
Boston Scientific 4Q Profit Up on Strong Cardio Device Sales
Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...